Cancers Of The Ocular Surface
AURAAura Biosciences IncCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Belzupacap Sarotalocan (AU-011) (Virus-Like Conjugate) in Cancers Of The Ocular Surface. The expected timing is based on the latest available company guidance and may change.
11/13/25:- Planning a Ph1 proof-of-concept trial of bel-sar for cancers of the ocular surface, assessing safety, feasibility and histopathologic tumor response at 2–4 weeks, with early proof-of-concept data from Australian clinical sites expected in 2026. 03/30/26:- Phase 1 proof-of-concept ocular surface cancer trial now initiating in Australia; early data still expected 2026. 05/11/26:- Phase 1 ocular surface cancer proof-of-concept trial initiating in Australia; early histopathologic response data expected in 2026. 08/11/26:- Ph1 ocular surface cancer program advancing; Q1 2027 update expected.
Verification
Confirm timing and program details against the company announcement or filing.